Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $17.00 Consensus Price Target from Brokerages

Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) have been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $17.00.

Several analysts have recently commented on the stock. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Vir Biotechnology in a research report on Tuesday, December 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Monday, December 22nd.

Vir Biotechnology Stock Up 2.2%

VIR stock opened at $7.56 on Friday. Vir Biotechnology has a twelve month low of $4.16 and a twelve month high of $11.30. The stock has a market cap of $1.05 billion, a P/E ratio of -2.09 and a beta of 1.39. The business’s 50-day moving average price is $6.19 and its 200-day moving average price is $5.63.

Vir Biotechnology (NASDAQ:VIR) last released its earnings results on Wednesday, November 5th. The company reported ($1.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.47). The firm had revenue of $0.24 million for the quarter, compared to the consensus estimate of $1.98 million. Vir Biotechnology had a negative return on equity of 50.76% and a negative net margin of 2,963.54%.Vir Biotechnology’s revenue was up .8% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.56) EPS. On average, equities research analysts expect that Vir Biotechnology will post -3.92 earnings per share for the current fiscal year.

Insider Transactions at Vir Biotechnology

In related news, CFO Jason O’byrne sold 6,799 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $5.56, for a total value of $37,802.44. Following the transaction, the chief financial officer directly owned 110,701 shares of the company’s stock, valued at approximately $615,497.56. The trade was a 5.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Vicki L. Sato sold 22,000 shares of the stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $5.93, for a total transaction of $130,460.00. Following the sale, the director directly owned 1,166,391 shares of the company’s stock, valued at approximately $6,916,698.63. This trade represents a 1.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 946,161 shares of company stock valued at $5,871,551 over the last 90 days. Company insiders own 16.00% of the company’s stock.

Hedge Funds Weigh In On Vir Biotechnology

Several institutional investors have recently bought and sold shares of VIR. ARCH Venture Management LLC purchased a new position in shares of Vir Biotechnology in the 2nd quarter worth $65,100,000. Millennium Management LLC lifted its holdings in shares of Vir Biotechnology by 129.2% in the 3rd quarter. Millennium Management LLC now owns 1,396,504 shares of the company’s stock valued at $7,974,000 after acquiring an additional 787,212 shares during the last quarter. Nordea Investment Management AB grew its position in Vir Biotechnology by 403.7% in the second quarter. Nordea Investment Management AB now owns 704,377 shares of the company’s stock worth $3,677,000 after acquiring an additional 564,537 shares in the last quarter. Clarius Group LLC increased its stake in Vir Biotechnology by 979.7% during the second quarter. Clarius Group LLC now owns 617,535 shares of the company’s stock worth $3,112,000 after acquiring an additional 560,342 shares during the last quarter. Finally, Aberdeen Group plc increased its stake in Vir Biotechnology by 51.6% during the third quarter. Aberdeen Group plc now owns 1,526,265 shares of the company’s stock worth $8,715,000 after acquiring an additional 519,374 shares during the last quarter. Institutional investors own 65.32% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.